Article
Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1.
Liver international : official journal of the International Association for the Study of the Liver - 1 Jun 2006
Fujiwara Keiichi, Yokosuka Osamu, Komine Fumihiko, Moriyama Mitsuhiko, Kato Naoya, Yoshida Haruhiko, Tanaka Naohide, Imazeki Fumio, Shiratori Yasushi, Arakawa Yasuyuki, Omata Masao
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV) RNA titer and HCV genotype are two major determinants of the outcome of interferon (IFN) monotherapy. To clarify the usefulness of combination therapy with IFN and ribavirin in Japanese hepatitis C patients, we treated patients with a relatively high dose of IFN in combination with ribavirin for 24 weeks and examined the effects in relation to the viral parameters. METHODS: Two...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.